CA-HALIO
16.11.2023 14:01:35 CET | Business Wire | Press release
HALIO, designer of the world’s fastest, most beautiful, eco-friendly, and technologically advanced electrochromic (smart) glass, and SKC Ltd., a leading company in the ESG Materials Solution industry based in South Korea, today announced that HALIO has raised up to $70M in funding from SKC to further market and develop the industry’s next generation of smart glass technology, focusing on energy savings, environmental impact, and creating beautiful facades, while enabling occupant wellness and comfort.
“This investment is expected to further expand our ESG strategy,” said SKC’s Vice President Junghwan Shin. “We strongly believe that HALIO has the most advanced smart glass technology that will significantly impact global energy savings and our environment,” emphasized Shin.
In conjunction with the funding announcement, HALIO also announced the appointment of Doug Schendt as the company's new CEO, replacing Bruce Sohn, who has served as CEO since 2020. Sohn is retiring after successfully leading the company through this latest milestone.
"I'm thrilled to take on this new role and lead HALIO into its next phase of growth," said Schendt. "Having previously led our Asia operations, I'm excited to now head HALIO globally. Bruce's vision and leadership have positioned us well, and I look forward to building on that strong foundation."
HALIO Smart Glass enables architects to design beautiful and elegant facades, supporting building owners’ pursuit of providing occupants with the most comfortable, productive, and healthy interior environments. HALIO’s Sky Camera, tint algorithms, and control automation, coupled with the industry’s fastest switching speed (within seconds), make HALIO the only smart glass solution that truly optimizes daylight control and solar heat gain management in real-time.
HALIO's smart glass technology reduces a building's operational energy use by up to 22%. It decreases peak demand by 25%, which is vital in balancing overstressed power grids (Red Car Analytics - Energy Efficiency Analysis of HALIO, Nov 2019). With countries now targeting buildings as major energy users, regulations increasingly require more efficient facades. Additionally, new incentives like the U.S. Investment Tax Credit reward owners for adding energy-saving solutions like HALIO Smart Glass.
"This new capital enables us to accelerate innovation in our smart glass technology as well as expand our reach in key markets like Asia, Europe, and the Middle East," added Sohn. "This is an incredibly exciting time for HALIO. I'm proud of what we've accomplished and am confident that with Doug as CEO, the company is in great hands to continue our mission and bring our products to customers globally."
About HALIO
HALIO Smart Glass is the world’s fastest and most advanced electrochromic (smart glass) technology, enabling maximum control of daylight while optimizing energy savings by reducing solar heat gain and minimizing glare. Powered by HALIO windows and skylights are available directly from the HALIO and third-party fabricators, including Viracon and GLASSBEL, with various glass coatings and configurations. Beautiful buildings deserve beautiful facades. Find out more what HALIO can do for your next building project at www.halioinc.com.
About SKC
For the past 40 years, SKC has focused on developing materials to create a better world, positioning today as a ‘Materials Solution Company’. SKC has recently reorganized its business portfolio, centering around rechargeable batteries, semiconductors, and eco-friendly materials. Our goal is to provide new values to customers with state-of-the-art technology and earn support and trust from both customers and society, with the vision of becoming a ‘Global Major ESG Eco-Friendly Materials Solution Company’. SKC will continue to make ceaseless challenge and innovation. Learn more: http://www.skc.co.kr/eng/main/index.do
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116891065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom